Sumati Rao

797 total citations
42 papers, 566 citations indexed

About

Sumati Rao is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sumati Rao has authored 42 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sumati Rao's work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (15 papers) and Melanoma and MAPK Pathways (8 papers). Sumati Rao is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (15 papers) and Melanoma and MAPK Pathways (8 papers). Sumati Rao collaborates with scholars based in United States, United Kingdom and Germany. Sumati Rao's co-authors include Komal Gupte-Singh, Ahmad A. Tarhini, Corey Ritchings, David F. McDermott, Michael B. Atkins, Mary Cifaldi, Alicia C. Shillington, Vibeke Strand, Eric Ruderman and Keith A. Betts and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sumati Rao

40 papers receiving 553 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sumati Rao United States	13	316	163	124	93	85	42	566
John Waller United Kingdom	10	107 0.3×	102 0.6×	57 0.5×	94 1.0×	50 0.6×	38	415
Michelle Rashford United States	7	226 0.7×	60 0.4×	59 0.5×	119 1.3×	30 0.4×	10	640
Jaime O. Herrera‐Cáceres Canada	10	103 0.3×	182 1.1×	86 0.7×	16 0.2×	49 0.6×	52	431
Ümit Tapan United States	11	180 0.6×	120 0.7×	121 1.0×	10 0.1×	23 0.3×	39	433
Brian Shinder United States	12	101 0.3×	172 1.1×	81 0.7×	29 0.3×	72 0.8×	31	335
Silvana Spadafora Canada	8	531 1.7×	130 0.8×	165 1.3×	9 0.1×	34 0.4×	22	661
Igor Stukalin Canada	12	314 1.0×	278 1.7×	126 1.0×	41 0.4×	11 0.1×	47	541
Judit Kocsis Hungary	9	164 0.5×	79 0.5×	87 0.7×	62 0.7×	28 0.3×	38	341
Oleg Shapiro United States	12	79 0.3×	230 1.4×	228 1.8×	12 0.1×	37 0.4×	55	511
Victor M. Schuettfort Germany	16	295 0.9×	380 2.3×	82 0.7×	21 0.2×	75 0.9×	63	747

Countries citing papers authored by Sumati Rao

Since Specialization

Citations

This map shows the geographic impact of Sumati Rao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumati Rao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumati Rao more than expected).

Fields of papers citing papers by Sumati Rao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumati Rao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumati Rao. The network helps show where Sumati Rao may publish in the future.

Co-authorship network of co-authors of Sumati Rao

This figure shows the co-authorship network connecting the top 25 collaborators of Sumati Rao. A scholar is included among the top collaborators of Sumati Rao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumati Rao. Sumati Rao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Masárová, Lucia, Srđan Verstovšek, Sumati Rao, et al.. (2023). PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN). HemaSphere. 7(S3). e9317412–e9317412. 1 indexed citations

Masárová, Lucia, et al.. (2023). POSTER: MPN-549 Transfusion-Related Cost and Time Burden Offsets in Patients With Myelofibrosis Treated With Momelotinib vs Best Available Therapy. Clinical Lymphoma Myeloma & Leukemia. 23. S192–S192. 1 indexed citations

Stenehjem, David D., Solomon J. Lubinga, Keith A. Betts, et al.. (2021). Treatment Patterns in Patients with Metastatic Non-Small-Cell Lung Cancer in the Era of Immunotherapy. Future Oncology. 17(22). 2940–2949. 14 indexed citations

Waterhouse, David, Jenny Lam, Keith A. Betts, et al.. (2021). Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 156. 41–49. 88 indexed citations

Waterhouse, David, Jenny Lam, Keith A. Betts, et al.. (2021). Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset. SHILAP Revista de lepidopterología. 37. 107195–107195. 3 indexed citations

Jang, Sekwon, et al.. (2020). Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma. Dermatology and Therapy. 10(5). 985–999. 12 indexed citations

Yang, Shuo, Michael B. Atkins, Sumati Rao, et al.. (2020). Clinical and Economic Outcomes of Treatment Sequences for Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma. Immunotherapy. 12(1). 37–51. 12 indexed citations

Deniz, Baris, Shuo Yang, Arman Altincatal, et al.. (2019). Treatment sequences for advanced renal cell carcinoma: A health economic assessment. PLoS ONE. 14(8). e0215761–e0215761. 15 indexed citations

Johnson, Courtney, et al.. (2019). Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. Journal of Medical Economics. 22(7). 662–670. 39 indexed citations

10.

Tarhini, Ahmad A., et al.. (2019). Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. Journal of Comparative Effectiveness Research. 8(7). 461–473. 14 indexed citations

11.

Nadler, Eric, Janet L. Espirito, Thomas W. Wilson, et al.. (2019). Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.. Journal of Clinical Oncology. 37(8_suppl). 119–119. 1 indexed citations

12.

Freeman, Morganna, Keith A. Betts, Shan Jiang, et al.. (2019). Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data. Advances in Therapy. 36(10). 2783–2796. 6 indexed citations

13.

McDermott, David F., Ruchit Shah, Komal Gupte-Singh, et al.. (2018). Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. Quality of Life Research. 28(1). 109–119. 14 indexed citations

14.

Deniz, Baris, Arman Altincatal, Sumati Rao, et al.. (2018). Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. PLoS ONE. 13(8). e0203406–e0203406. 1 indexed citations

15.

Freeman, Morganna, Alexander N. Shoushtari, Keith A. Betts, et al.. (2018). Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma.. Journal of Clinical Oncology. 36(15_suppl). 9594–9594. 2 indexed citations

16.

Liu, Jun S. & Sumati Rao. (2015). Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma. Experimental Hematology and Oncology. 5(1). 9–9. 1 indexed citations

17.

Margolin, Kim, Ahmad A. Tarhini, Sumati Rao, et al.. (2015). Effectiveness and safety of ipilimumab therapy in advanced melanoma: evidence from clinical practice sites in the US. The Journal of Community and Supportive Oncology. 13(4). 131–138. 5 indexed citations

18.

Patt, Debra A., et al.. (2014). A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting. Journal of Cancer Therapy. 5(12). 1049–1058. 4 indexed citations

19.

Rao, Sumati, et al.. (2012). Squamous Cell Carcinoma and Pleomorphic Sarcoma (MFH) Arising in a Mature Cystic Teratoma of the Ovary. International Journal of Gynecological Pathology. 31(5). 443–446. 7 indexed citations

20.

Rao, Sumati, William B. Carter, Donna Mapes, et al.. (2000). Development of subscales from the symptoms/problems and effects of kidney disease scales of the kidney disease quality of life instrument. Clinical Therapeutics. 22(9). 1099–1111. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact